• 1
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:220818.
  • 2
    Moe SM, Drüeke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Clin Calcium 2007;17:18304.
  • 3
    National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl. 3):S1202.
  • 4
    Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44: 348.
  • 5
    Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int 2006;70, S37.
  • 6
    Tominaga Y, Matsuoka S, Sato T. Surgical indication and procedure of parathyroidectomy in patients with chronic kidney disease. Ther Apher Dial 2005;9:447.
  • 7
    Tokumoto M, Taniguchi M, Matsuo D et al. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors. Ther Apher Dial 2005;9:S2734.
  • 8
    Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:143643.
  • 9
    Yano S, Sugimoto T, Tsukamoto T et al. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol 2003;148:40311.
  • 10
    Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients guideline. Therap Apher Dial 2008;12:51425.
  • 11
    Andress DL. Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. Drugs 2007;67:19992012.
  • 12
    Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Drugs 2007;67:198198.
  • 13
    Wu-Wong JR. The potential for vitamin D receptor activation in cardiovascular research. Kidney Int 2007;72:2379.
  • 14
    Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Clin Calcium 2007;17:76771.
  • 15
    Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key role in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005;288:F25364.
  • 16
    Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997;100:297783.
  • 17
    Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:101724.
  • 18
    Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2005;109:33965.
  • 19
    Block GA, Martin KJ, De Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:151625.
  • 20
    Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:8007.
  • 21
    Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:57583.
  • 22
    Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:76071.
  • 23
    Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793800.
  • 24
    Block GA, Steven Zeig S, Jared Sugihara J et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008;23:231118.
  • 25
    Messa P, Macário F, Yaqoob M et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:3645.
  • 26
    Elder J. Parathyroidectomy in the calcimimetic era. Nephrology 2005;10:51115.
  • 27
    Tominaga Y, Matsuoka S, Uno N, Sato T. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 2008;12(Suppl 1):S216.
  • 28
    Fukagawa M, Okazaki R, Takano K et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990;323:4212.
  • 29
    Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994;45:171021.
  • 30
    Onoda N, Kurihara S, Sakurai Y et al. Evaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathology. Nephrol Dial Transplant 2003;18(Suppl 3):iii34iii37.
  • 31
    Matsuoka S, Tominaga Y, Sato T et al. Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism. Ther Apher Dial 2008;12:3915.
  • 32
    Vulpio C, Bossola M, De Gaetano A et al. Ultrasound patterns of parathyroid glands in chronic hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 2008;28:58997.
  • 33
    Tominaga Y. Basic and clinical aspects of calcimimetics. Calcimimetic is indicated for patients with surgically uncontrollable hyperparathyroidism Clin Calcium 2008;18:6771.
  • 34
    Narayan R, Perkins RM, Berbano EP et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007;49:80113.
  • 35
    Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 2007;13:397411.
  • 36
    Garside R, Pitt M, Anderson R, Mealing S, D'Souza R, Stein K. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007;22:142836.
  • 37
    National Institute for Health and Clinical Excellence (NICE). Cinacalcet for the treatment of secondary hyperthyroidism in patients with end-stage renal disease on maintenance dialysis therapy. NICE Technology Appraisal Guidance 117. January 2007:427.
  • 38
    Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 2000;11:90311.
  • 39
    Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005;67:46776.
  • 40
    Naveh-Many T, Rahamimov R, Livni N et al. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995;96:178693.
  • 41
    Terawaki H, Nakano H, Takeguchi F et al. Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant 2009;24:6901.
  • 42
    Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007;22:182839.